Consensus study reveals significant interpretation discrepancies in HER2-low and ultralow breast cancer, suggesting the need for clearer definitions.
Experts had significant discrepancies in interpreting HER2-low/ultralow status. It is important to assess if the distinction between HER2-low and ultralow is strictly required and if HER2-null breast cancer exists in reality.
No takes yet. Share an insight, caveat, or question.
Koh et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: